mRNA/LNP Formulations from Therapeutics to Vaccines

3/22/2022 11:15 - 11:45

  • mRNA as therapeutic modality
  • Improvements of LNP formulations
  • Impact of expression kinetics and protein half-life
  • Vaccine applications and future developments

Erik Oude Blenke, Associate Principle Scientist, AstraZeneca